Tiziana Life Sciences PLC TLSA to Host Call to Discuss Exclusive License
07 Settembre 2021 - 8:00AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
07 September 2021
Tiziana to Host Investor Call to Discuss Exclusive License
Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3
Monoclonal Antibody, in Conjunction with Allogeneic CAR T
Candidates for Cancer Treatment
NEW YORK and LONDON, September 7, 2021 - Tiziana Life Sciences
plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation, and infectious diseases, will host a
conference call and audio webcast on Wednesday, September 8, at
4:15 p.m. ET to discuss its recently announced exclusive license
agreement to evaluate Foralumab, the Company's novel, fully human
anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T
candidates for cancer treatment.
Date: Wednesday, September 8, 2021
Time: 4:15 p.m. Eastern Time
Live Call: +1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)
Webcast: http://public.viavid.com/index.php?id=146493
For interested individuals unable to join the conference call, a
dial-in replay of the call will be available until September 22,
2021 and can be accessed by dialing +1-844-512-2921 (U.S. Toll
Free) or +1-412-317-6671 (International) and entering replay pin
number: 13722965.
About Foralumab
Foralumab (TZLS-401, formerly NI-0401), the only entirely human
anti-CD3 mAb, shows reduced release of cytokines as compared to
other anti-CD3 mAbs after IV administration in patients with
Crohn's disease with decreases in the classic side effects of
cytokine release syndrome and improves the overall safety profile
of Foralumab. In a humanized mouse model (NOD/SCID
IL2<GAMMA>c-/-), it was shown that while targeting the T cell
receptor, orally administered Foralumab modulates immune responses
of the T cells, enhances regulatory T-cells (Tregs) and thus
provides therapeutic benefit in treating inflammatory and
autoimmune diseases without the occurrence of potential adverse
events usually associated with parenteral mAb therapy (Ogura M. et
al., 2017 Clin Immunol 183, 240-246). Based on animal studies, the
nasal and oral administration of Foralumab offers the potential for
the immunotherapy of autoimmune and inflammatory diseases in a safe
manner by the induction of Tregs.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ:TLSA, UK LSE:
TILS) biotechnology company that focuses on the discovery and
development of novel molecules to treat human diseases in oncology,
inflammation and infectious diseases. In addition to Milciclib, the
Company will be shortly initiating Phase 2 studies with orally
administered Foralumab for Crohn's Disease and nasally administered
Foralumab for progressive multiple sclerosis. Foralumab is the only
fully human anti-CD3 monoclonal antibody ("mAb") in clinical
development in the world. This Phase 2 compound has potential
application in a wide range of autoimmune and inflammatory
diseases, such as Crohn's Disease, multiple sclerosis, type-1
diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and
rheumatoid arthritis, where modulation of a T-cell response is
desirable. The Company is accelerating development of
anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further enquiries:
United Kingdom:
Tiziana Life Sciences plc +44 (0)20 7495 2379
Gabriele Cerrone, Chairman, and founder
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGZGGLGVZGMZZ
(END) Dow Jones Newswires
September 07, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Tiziana Life Sciences (LSE:TILS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Tiziana Life Sciences (LSE:TILS)
Storico
Da Giu 2023 a Giu 2024